Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery 6/2019

01.06.2019 | Original Article

Outcomes and predictive factors for pathological node-positive in radiographically pure-solid, small-sized lung adenocarcinoma

verfasst von: Hiroyuki Kayata, Mitsuhiro Isaka, Yukihiro Terada, Kiyomichi Mizuno, Yoshiyuki Yasuura, Hideaki Kojima, Yasuhisa Ohde

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The indication of limited resection for radiographically pure-solid, small-sized lung adenocarcinoma is controversial. This study aimed to reveal the long-term outcome of standard surgical treatment and determine the predictive factors for pathological lymph node metastasis in optimal candidates undergoing limited surgical resection for pure-solid, small-sized lung adenocarcinoma.

Methods

The medical records of 107 consecutive patients were retrospectively reviewed at our hospital between December 2002 and December 2013. Inclusion criteria were histopathological diagnosis of lung adenocarcinoma, radiographically pure-solid tumor, ≤ 2 cm tumor size measured using thin-section computed tomography, clinical N0M0, patients who underwent lobectomy with systematic or lobe-specific lymph node dissection, and R0 resection. Overall and disease-free survival curves were calculated using the Kaplan–Meier method. Clinicopathological factors predicting pathological node-positive metastasis were identified by univariate and multivariate analysis.

Results

The 5-year overall and disease-free survival rates were 91.4% and 87.3%, respectively. Multivariate analysis demonstrated maximum standardized uptake value > 5 as the independent predictor of pathological node-positive metastasis (odds ratio 3.81; 95% confidence interval 1.25–12.3; p = 0.02). In all patients, the pathological node-positive rate was 16.7%; in patients who had a maximum standardized uptake value of ≤ 5, the rate was 7.9%.

Conclusion

The long-term outcome of standard surgical treatment was favorable. Maximum standardized uptake value was a significant predictor of pathological node-positive metastasis; however, diagnostic accuracy was not favorable. Therefore, the selection of optimal candidates is difficult, and limited surgical resection may not be applicable in pure-solid, small-sized lung adenocarcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRef National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRef
2.
Zurück zum Zitat Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Endo S, Natsugoe S, Shimizu H, et al. Thoracic and cardiovascular surgery in Japan during 2015: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2018. https://doi.org/10.1007/s11748-018-0968-0.CrossRef Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Endo S, Natsugoe S, Shimizu H, et al. Thoracic and cardiovascular surgery in Japan during 2015: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2018. https://​doi.​org/​10.​1007/​s11748-018-0968-0.CrossRef
3.
Zurück zum Zitat Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eight edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:1204–23.CrossRefPubMed Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eight edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:1204–23.CrossRefPubMed
4.
Zurück zum Zitat Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H, Nagai K, et al. Japan Lung Cancer Surgical Study Group (JCOG LCSSG). A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011;6:751–6.CrossRefPubMed Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H, Nagai K, et al. Japan Lung Cancer Surgical Study Group (JCOG LCSSG). A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011;6:751–6.CrossRefPubMed
5.
Zurück zum Zitat Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K. Neither Maximum tumor size nor solid component size is prognostic in part-solid lung cancer: impact of tumor size should be applied exclusively to solid lung cancer. Ann Thorac Surg. 2016;102:407–15.CrossRefPubMed Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K. Neither Maximum tumor size nor solid component size is prognostic in part-solid lung cancer: impact of tumor size should be applied exclusively to solid lung cancer. Ann Thorac Surg. 2016;102:407–15.CrossRefPubMed
6.
Zurück zum Zitat Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014;145:66–71.CrossRef Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014;145:66–71.CrossRef
7.
Zurück zum Zitat Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Segmentectomy for clinical stage IA lung adenocarcinoma showing solid dominance on radiology. Eur J Cardiothorac Surg. 2014;46:637–42.CrossRefPubMed Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Segmentectomy for clinical stage IA lung adenocarcinoma showing solid dominance on radiology. Eur J Cardiothorac Surg. 2014;46:637–42.CrossRefPubMed
8.
Zurück zum Zitat Wilshire CL, Louie BE, Manning KA, Horton MP, Castiglioni M, Gorden JA, et al. Radiologic evaluation of small lepidic adenocarcinomas to guide decision making in surgical resection. Ann Thorac Surg. 2015;100:979–88.CrossRefPubMed Wilshire CL, Louie BE, Manning KA, Horton MP, Castiglioni M, Gorden JA, et al. Radiologic evaluation of small lepidic adenocarcinomas to guide decision making in surgical resection. Ann Thorac Surg. 2015;100:979–88.CrossRefPubMed
9.
Zurück zum Zitat Inoue M, Minami M, Sawabata N, Utsumi T, Kadota Y, Shigemura N, et al. Clinical outcome of resected solid-type small-sized c-stage IA non-small cell lung cancer. Eur J Cardiothorac Surg. 2010;37:1445–9.CrossRefPubMed Inoue M, Minami M, Sawabata N, Utsumi T, Kadota Y, Shigemura N, et al. Clinical outcome of resected solid-type small-sized c-stage IA non-small cell lung cancer. Eur J Cardiothorac Surg. 2010;37:1445–9.CrossRefPubMed
10.
Zurück zum Zitat Hattori A, Suzuki K, Matsunaga T, Fukui M, Kitamura Y, Miyasaka Y, et al. Is limited resection appropriate for radiologically “solid” tumors in small lung cancers? Ann Thorac Surg. 2012;94:212–5.CrossRefPubMed Hattori A, Suzuki K, Matsunaga T, Fukui M, Kitamura Y, Miyasaka Y, et al. Is limited resection appropriate for radiologically “solid” tumors in small lung cancers? Ann Thorac Surg. 2012;94:212–5.CrossRefPubMed
11.
Zurück zum Zitat Kudo Y, Matsubayashi J, Saji H, Akata S, Shimada Y, Kato Y, et al. Association between high-resolution computed tomography findings and the IASLC/ATS/ERS classification of small lung adenocarcinomas in Japanese patients. Lung Cancer. 2015;90:47–54.CrossRefPubMed Kudo Y, Matsubayashi J, Saji H, Akata S, Shimada Y, Kato Y, et al. Association between high-resolution computed tomography findings and the IASLC/ATS/ERS classification of small lung adenocarcinomas in Japanese patients. Lung Cancer. 2015;90:47–54.CrossRefPubMed
12.
Zurück zum Zitat Okada M, Yoshikawa K, Hatta T, Tsubota N. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small-cell lung cancer of 2 cm or smaller? Ann Thorac Surg. 2001;71:956–61.CrossRefPubMed Okada M, Yoshikawa K, Hatta T, Tsubota N. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small-cell lung cancer of 2 cm or smaller? Ann Thorac Surg. 2001;71:956–61.CrossRefPubMed
13.
Zurück zum Zitat Yoshikawa K, Tsubota N, Kodama K, Ayabe H, Taki T, Mori T. Prospective study of extended segmentectomy for small lung tumors: the final report. Ann Thorac Surg. 2002;73:1055–9.CrossRefPubMed Yoshikawa K, Tsubota N, Kodama K, Ayabe H, Taki T, Mori T. Prospective study of extended segmentectomy for small lung tumors: the final report. Ann Thorac Surg. 2002;73:1055–9.CrossRefPubMed
14.
Zurück zum Zitat Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132:769–75.CrossRefPubMed Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132:769–75.CrossRefPubMed
15.
Zurück zum Zitat Koike T, Kitahara A, Sato S, Hashimoto T, Aoki T, Koike T, et al. Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer. Ann Thorac Surg. 2016;101:1354–60.CrossRefPubMed Koike T, Kitahara A, Sato S, Hashimoto T, Aoki T, Koike T, et al. Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer. Ann Thorac Surg. 2016;101:1354–60.CrossRefPubMed
16.
Zurück zum Zitat Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with Non-small-cell lung cancer ≤ 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34:3175–82.CrossRefPubMed Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with Non-small-cell lung cancer ≤ 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34:3175–82.CrossRefPubMed
17.
Zurück zum Zitat Khullar OV, Liu Y, Gillespie T, Higgins KA, Ramalingam S, Lipscomb J, et al. Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer. An analysis from the national cancer data base. J Thorac Oncol. 2015;10:1625–33.CrossRefPubMedPubMedCentral Khullar OV, Liu Y, Gillespie T, Higgins KA, Ramalingam S, Lipscomb J, et al. Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer. An analysis from the national cancer data base. J Thorac Oncol. 2015;10:1625–33.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer ≤ 1 cm in size. A review of SEER data. Chest. 2011;139:491–6.CrossRefPubMed Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer ≤ 1 cm in size. A review of SEER data. Chest. 2011;139:491–6.CrossRefPubMed
19.
Zurück zum Zitat Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less or be more? –A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer. 2015;89:121–32.CrossRefPubMed Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less or be more? –A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer. 2015;89:121–32.CrossRefPubMed
20.
Zurück zum Zitat Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.CrossRefPubMed Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.CrossRefPubMed
21.
Zurück zum Zitat Altorki N, Pass H, Miller D, Kernstine K, et al. A phase III randomized trial of lobectomy versus sublobar resection for small (≤ 2 cm) peripheral non-small cell lung cancer. https://clinicaltrials.gov/. Accessed 9 May 2018. Altorki N, Pass H, Miller D, Kernstine K, et al. A phase III randomized trial of lobectomy versus sublobar resection for small (≤ 2 cm) peripheral non-small cell lung cancer. https://​clinicaltrials.​gov/​. Accessed 9 May 2018.
22.
Zurück zum Zitat Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg. 2012;144:1365–71.CrossRefPubMed Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg. 2012;144:1365–71.CrossRefPubMed
23.
Zurück zum Zitat Ye B, Cheng M, Li W, Ge XX, Geng JF, Feng J, et al. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014;98:217–23.CrossRefPubMed Ye B, Cheng M, Li W, Ge XX, Geng JF, Feng J, et al. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014;98:217–23.CrossRefPubMed
24.
Zurück zum Zitat Moon Y, Kim KS, Lee KY, Sung SW, Kim YK, Park JK. Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg. 2016;101:1928–35.CrossRefPubMed Moon Y, Kim KS, Lee KY, Sung SW, Kim YK, Park JK. Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg. 2016;101:1928–35.CrossRefPubMed
25.
Zurück zum Zitat Zhang J, Chen L, Chen Y, Wang W, Cheng L, Zhou X, et al. Tumor vascularity and glucose metabolism correlated in adenocarcinoma, but not in squamous cell carcinoma of the lung. PLoS ONE. 2014;9:e91649.CrossRefPubMedPubMedCentral Zhang J, Chen L, Chen Y, Wang W, Cheng L, Zhou X, et al. Tumor vascularity and glucose metabolism correlated in adenocarcinoma, but not in squamous cell carcinoma of the lung. PLoS ONE. 2014;9:e91649.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J, et al. Difference in prognostic significance of maximum standardized uptake value on [18F]-Fluoro-2-Deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol. 2011;41:890–6.CrossRefPubMed Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J, et al. Difference in prognostic significance of maximum standardized uptake value on [18F]-Fluoro-2-Deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol. 2011;41:890–6.CrossRefPubMed
27.
Zurück zum Zitat Rena O, Boldorini R, Papalia E, Turello D, Massera F, Davoli F, et al. Metastasis to subsegmental and segmental lymph nodes in patients resected for non-small cell lung cancer: prognostic impact. Ann Thorac Surg. 2014;97:987–92.CrossRefPubMed Rena O, Boldorini R, Papalia E, Turello D, Massera F, Davoli F, et al. Metastasis to subsegmental and segmental lymph nodes in patients resected for non-small cell lung cancer: prognostic impact. Ann Thorac Surg. 2014;97:987–92.CrossRefPubMed
28.
Zurück zum Zitat Yamanaka A, Hirai T, Fujimoto T, Ohtake Y, Konichi F. Analyses of segmental lymph node metastases and intrapulmonary metastases of small lung cancer. Ann Thorac Surg. 2000;70:1624–8.CrossRefPubMed Yamanaka A, Hirai T, Fujimoto T, Ohtake Y, Konichi F. Analyses of segmental lymph node metastases and intrapulmonary metastases of small lung cancer. Ann Thorac Surg. 2000;70:1624–8.CrossRefPubMed
29.
Zurück zum Zitat Wang L, Jiang W, Zhan C, Shi Y, Zhang Y, Lin Z, et al. Lymph node metastasis in clinical stage IA peripheral lung cancer. Lung Cancer. 2015;90:41–6.CrossRefPubMed Wang L, Jiang W, Zhan C, Shi Y, Zhang Y, Lin Z, et al. Lymph node metastasis in clinical stage IA peripheral lung cancer. Lung Cancer. 2015;90:41–6.CrossRefPubMed
30.
Zurück zum Zitat Okada M, Nakayama H, Okumura S, Daisaki H, Adachi S, Yoshimura M, et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141:1384–91.CrossRefPubMed Okada M, Nakayama H, Okumura S, Daisaki H, Adachi S, Yoshimura M, et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141:1384–91.CrossRefPubMed
Metadaten
Titel
Outcomes and predictive factors for pathological node-positive in radiographically pure-solid, small-sized lung adenocarcinoma
verfasst von
Hiroyuki Kayata
Mitsuhiro Isaka
Yukihiro Terada
Kiyomichi Mizuno
Yoshiyuki Yasuura
Hideaki Kojima
Yasuhisa Ohde
Publikationsdatum
01.06.2019
Verlag
Springer Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 6/2019
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-018-01059-2

Weitere Artikel der Ausgabe 6/2019

General Thoracic and Cardiovascular Surgery 6/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.